Cardiovascular, Renal and Metabolism (CVRM)
Saving lives by seeing the full picture and jointly addressing cardio-renal-metabolic risks
CaReMe: A World of Close Collaborative Care for CVRM Patients
At AstraZeneca, CVRM is one of our main therapy areas because science continues to uncover commonalities between cardiovascular, renal and metabolic diseases. With this knowledge, we are daring to do things differently by shifting focus from treating patients with a single disease, to addressing overlapping disease areas and risk factors. This is why we created a distinct approach to care for CVRM – CaReMe. This new approach gives us the chance to save vital time and valuable healthcare resources, and most importantly improve patient lives.
Cardiovascular, renal and metabolic diseases kill over 20 million people each year1 and despite the close associations between the three disease areas, shared risk factors are still often not diagnosed or addressed2. For example, if you are an adult with type-2 diabetes, you could be 1.8 times more likely to be hospitalised for a heart attack3. And if we look at diabetes and kidney disease combined, life expectancy can be reduced by up to 15 years for men and 16 years for women4.
We have made it our mission to help save the lives of these patients by jointly addressing CVRM disease risk factors. We work with cardiovascular, renal and diabetes experts from around the world, who are led by science and fuelled by investigation to adapt a proactive, collaborative, and multidisciplinary approach to patient care. We want to go beyond treatment to build and support the right infrastructure for CaReMe, and we can do this by fostering communication between departments and promoting interdisciplinary coordination amongst specialists and primary care physicians.
By taking risks in research, science and investigation, we systematically study compounds across the CVRM diseases and in different combinations – striving to create uncharted pathways of clinical exploration. This first-class clinical research and real-world evidence help us understand the interactions between two or more conditions, and how the deterioration of one condition could adversely affect the others. It also sets the stage for our pioneering approach in the fields of disease regression and organ regeneration, putting us a step closer to making science fiction a reality.
Driven by collaboration
We cannot change the future alone. We are actively investing in broader and stronger partnerships with respected academic institutions, research organisations, patient advocacy groups, and healthcare companies. We are paving the way for clinical practice evolution, and we are using close collaboration as our brick foundation. As facilitators of the CaReMe approach, we make it our responsibility to help healthcare professionals connect the dots, evolve their clinical practice and provide complete, potentially life-saving care for CVRM patients. Our role is to offer healthcare professionals the best possible solutions to enable them to think holistically and work in closer collaboration during everyday care and across individual specialties. Most importantly, it is through partnering with general practitioners that they can protect patients against heart and renal failure, improve health and save the lives of millions of people living with these diseases.
Joslin Diabetes Center
We are collaborating with the Joslin Diabetes Center at the Harvard Medical School to identify novel factors that could enhance pancreatic beta cell mass and function, or reverse beta cell dysfunction, to potentially prevent or stop the progression of diabetes. Three initial projects have been identified, focusing on several key areas including protecting and regenerating the insulin producing beta cells, with the potential for more projects to be added as new compelling science is identified.
To assist with our commitment to developing new therapies for the prevention and treatment of diabetes, obesity and related metabolic disorders, we have entered a research alliance with Michigan Medicine. Our researchers will utilise cutting-edge technologies to study genetic models and identify targets for treatment.
Our focus on unmet needs
Signs and symptoms do exist for moderate to severe atherosclerosis; however, it may not be diagnosed until after a heart attack or stroke. Read more
Signs and symptoms do exist for moderate to severe atherosclerosis; however, it may not be diagnosed until after a heart attack or stroke.
There are 38 million heart failure patients worldwide, with many suffering from at least one other underlying condition such as type-2 diabetes.
Chronic kidney disease (CKD) is a complex, debilitating condition with 200 million adults diagnosed worldwide. Read more
Diabetes is a growing disease and an enormous global burden that is currently projected to affect more than 592 million people by the year 2035.
Helping save lives by jointly addressing cardio-renal-metabolic risks
Watch how our unique science-driven strategy in cardiovascular, renal and metabolism is helping us to complete the picture.
Understanding the common mechanisms and how CVRM diseases interact
Learn more about our ambition to launch the CaReMe approach.
Understanding the importance of addressing CVRM diseases together
Find out how CaReMe can be put into action to help combat the burden of CVRM diseases.
Our early-to-late stage pipeline for CVRM
Today, with our CaReMe approach we believe we are the only pharmaceutical company with a full portfolio of potential CVRM solutions. With more than 25 therapies and therapy combinations in our early-to-late stage pipeline, we seek to bring real science to life, combatting conditions like CKD, ACS, and CHF.
MEDI0382 is a dual-peptide molecule that impacts insulin secretion and glucose homeostasis. It is under development for type-2 diabetes patients and may hold potential for other metabolic diseases.
MEDI5884 is designed to enhance reverse cholesterol transport and increase functional HDL. Its development is aimed to help prevent secondary CV events after a heart attack and may have potential for primary prevention in high-risk patients.
DapaCare is a clinical programme aimed at better understanding the cardiovascular and renal profile of dapagliflozin in people with and without type-2 diabetes. The programme will enrol nearly 30,000 patients in randomised clinical trials and generate data across a spectrum of people with established cardiovascular disease, cardiovascular risk factors and renal disease, providing evidence on the effects on patient outcomes.
Phase 3/LCM Projects: refers to assets that are pivotal in Phase II/III, or that have been submitted for regulatory approval, and may include assets that are now launched in one or more major markets (removed when launched in all applicable major markets).
Cardiovascular, Renal and Metabolism (as at 14 February 2019)
Our medicines are approved in individual countries for specific uses and the information we provide for patients is governed by local regulations. You should visit your local AstraZeneca site to find out more about our medicines in your country. In some countries we are not allowed to provide very much, or sometimes any, information on our prescription medicines so you should seek alternative trustworthy sources. Always ask a healthcare professional for advice about medicines.
Sharing clinical trials information
Phase III OLYMPUS and ROCKIES trials for roxadustat met their primary endpoints in chronic kidney disease patients with anaemia
Roxadustat approved in China for the treatment of anaemia in chronic kidney disease patients on dialysis
Survey insights help deepen our understanding of patients' experience of anaemia in chronic kidney disease to address this critical unmet need
The landmark DECLARE-TIMI 58 cardiovascular outcomes trial of Farxiga in patients with type-2 diabetes to be featured at AHA 2018
Be part of a journey where we see the patient as a whole, find solutions to treat CVRM diseases together and help us continue our work as an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.
- Wang H et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: A systematic analysis for the Global Burden of Disease Study 2015. The Lancet 2016; 388(10053):1459–544.
- Edelman Intelligence Relevance and barriers amongst EU specialists Survey 2018. Document ID: Z2-0050 | Date of preparation: August 2018 | Date of expiry: July 2020
- Centers for Disease Control and Prevention (CDC). National Diabetes Statistics Report, 2014: Centers for Disease Control and Preventions Division of Diabetes Translation [cited 2018 Jul 25]. Available from: URL: https://www.cdc.gov/diabetes/pdfs/data/2014-report-estimates-of-diabetes-and-its-burden-in-the-united-states.pdf.
- Wen CP et al. Diabetes with early kidney involvement may shorten life expectancy by 16 years. Kidney Int 2017; 92(2):388–96.
Veeva ID: Z4-14289
Date of next review: December 2020